Market Challenge - High initial investment costs

Global clinical chemistry analyzers market growth can be hampered due to high initial investment costs associated with setting up laboratories and purchasing advanced analyzers. Clinical chemistry analyzers equipped with latest technologies can cost anywhere between USD 50,000 to USD 300,000. Setting up the necessary laboratory infrastructure along with recurring costs of reagents, maintenance and skilled personnel further increases the overall expenditures. This high capital requirement poses a major restraint for small and medium hospitals as well as diagnostic centers in developing countries to automate their laboratories. The upfront investment decelerates the overall adoption rate of clinical chemistry analyzers devices. Moreover, budgetary constraints of public health systems also limit new procurement. To address this challenge, market players could offer flexible financing options and rental models to lower the entry barriers for customers.

Market Opportunity- Growth in point-of-care testing

Rising demand for point-of-care testing can offer lucrative opportunities for global clinical chemistry analyzers market players. Point-of-care testing employs portable devices that can be used near the patient in various settings to provide quick diagnostic results. It eliminates turnaround times for sending samples to central laboratories. Growing preference for self-monitoring and home-based testing can boost demand for point-of-care testing. Furthermore, increasing incidence of chronic and infectious diseases necessitates rapid testing solutions. Point-of-care analyzers suitable for resource-limited areas are gaining adoption in ambulatory surgical centers, physicians' offices, nursing homes and clinics. Market leaders are increasingly focusing on developing compact analyzers with upgraded features to capitalize on the expanding point-of-care testing domain.